Enasidenib (AG-221), a potent oral inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) enzyme, induces hematologic responses in patients with myelodysplastic syndromes (MDS) Meeting Abstract

  

Authors:	Stein, E. M.; Fathi, A. T.; DiNardo, C. D.; Pollyea, D. A.; Swords, R. T.; Roboz, G. J.; Collins, R.; Sekeres, M. A.; Stone, R. M.; Attar, E. C.; Tosolini, A.; Xu, Q.; Amatangelo, M.; Gupta, I.; Knight, R. D.; De Botton, S.; Tallman, M. S.; Kantarjian, H. M.
Abstract Title:	Enasidenib (AG-221), a potent oral inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) enzyme, induces hematologic responses in patients with myelodysplastic syndromes (MDS)
Meeting Title:	58th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	128
Issue:	22
Meeting Dates:	2016 Dec 3-6
Meeting Location:	San Diego, CA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2016-12-02
Language:	English
ACCESSION:	WOS:000394446805016
PROVIDER:	wos
DOI:	10.1182/blood.V128.22.343.343
Notes:	Meeting Abstract: 343 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/127379